Literature DB >> 19243003

A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts.

Edward Alabraba1, Peter Nightingale, Bridget Gunson, Stefan Hubscher, Simon Olliff, Darius Mirza, James Neuberger.   

Abstract

Previously, we have found that the absence of the colon after liver transplantation (LT) protects the patient from recurrent primary sclerosing cholangitis (rPSC). As our previous observation has not been confirmed in other series, we have reviewed our cohort of patients grafted for primary sclerosing cholangitis (PSC) with greater numbers and longer follow-up to reassess the rate, consequences, and risk factors for rPSC. We collected data on patients who underwent LT for PSC between January 1986 and April 2006. Data were collected for cytomegalovirus status, inflammatory bowel disease status, time of colectomy, type of colectomy, donor-recipient gender mismatch, recipient sex, extended donor criteria (EDC), and donor risk index. Accepted criteria were used to diagnose rPSC. Of a total of 230 consecutive adult patients, 61 (27%) underwent colectomy pre-/peri-LT, and 54 (23.5%) developed rPSC at a median of 4.6 (range, 0.5-12.9) years post-LT. A total of 263 deceased donor grafts were used, and 73 were EDC grafts. A diagnosis of rPSC was made in 61 of the 263 grafts (23%). The recurrence-free patient survival was significantly better (P < 0.05) in patients who underwent pre-/peri-LT colectomy and in those with non-EDC grafts. In conclusion, in this larger cohort of 230 patients and with longer follow-up of 82.5 (range, 0.0-238.6) months [in comparison with the previous report of 152 recipients with a follow-up of 52.8 (range, 1-146) months], we have shown that colectomy remains a significant risk factor for rPSC and that colectomy before and during initial LT for PSC confers a protective effect against rPSC in subsequent graft(s). Moreover, we have shown that EDC grafts are also a significant risk factor for rPSC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19243003     DOI: 10.1002/lt.21679

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  56 in total

Review 1.  Primary sclerosing cholangitis: is any treatment worthwhile?

Authors:  Ashley Barnabas; Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

Authors:  Mai Sedki; Cynthia Levy
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 3.  Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Authors:  Bettina M Buchholz; Panagis M Lykoudis; Reena Ravikumar; Joerg M Pollok; Giuseppe K Fusai
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

4.  Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.

Authors:  Yan-Hua Lai; Wei-Dong Duan; Qiang Yu; Sheng Ye; Nian-Jun Xiao; Dong-Xin Zhang; Zhi-Qiang Huang; Zhan-Yu Yang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 5.  Controversies in the management of primary sclerosing cholangitis.

Authors:  Jeremy S Nayagam; Stephen P Pereira; John Devlin; Phillip M Harrison; Deepak Joshi
Journal:  World J Hepatol       Date:  2016-02-18

Review 6.  Primary sclerosing cholangitis as an intractable disease.

Authors:  Sumihito Tamura; Yasuhiko Sugawara; Norihiro Kokudo
Journal:  Intractable Rare Dis Res       Date:  2012-02

Review 7.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 8.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 9.  Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis.

Authors:  Andreas Pascher; Maxim Nebrig; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2013-03-08       Impact factor: 5.594

Review 10.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.